Back to Ensign Peak Advisors, Inc Ensign Peak Advisors, Inc

PTGXPTGX

Showing 8 of 23 quarters

Position history for Ensign Peak Advisors, IncEnsign Peak Advisors, Inc's holdings in PROTAGONIST THERAPEUTICS INC

Yes. Ensign Peak Advisors holds 3,786 shares of PTGX (Protagonist Therapeutics), worth $464,088, as of its Q2 2026 13F filing. It reduced the position by 700 shares (-15.6%) from Q1 2026. Ensign Peak Advisors has held PTGX since Q2 2023, across 13 quarterly 13F filings.

Current Value

$464,088

Current Shares

3,786

Total Value Change

-$752,532

Total Shares Change

-23,250

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
3,786
-15.6%
$464,0880.0%$122.58
0
2026-Q1
Unchanged
4,486
0.0%
$472,8240.0%$105.40
0
2025-Q4
Decreased
4,486
-59.2%
$391,8070.0%$87.34
0
2025-Q3
Decreased
10,986
-52.5%
$729,8000.0%$66.43
0
2025-Q2
Decreased
23,136
-14.4%
$1.3M0.0%$55.27
0
2025-Q1
Unchanged
27,036
0.0%
$1.3M0.0%$48.36
0
2024-Q4
Unchanged
27,036
0.0%
$1M0.0%$38.60
0
2024-Q3
Unchanged
27,036
0.0%
$1.2M0.0%$45.00
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used